Scientists Just Discovered A Potential New Alzheimer's Cause
The exact cause of Alzheimer's disease has long evaded scientists, but experts typically suggest there are likely several factors (like genetics, environment, and lifestyle) that contribute to its development. We already know that getting good sleep, exercise, a heart-healthy diet, and regular socialization can lower your risk for the disease. But no one has yet been able to pinpoint why some develop the devastating condition while others don't. Now, new research published in the journal Alzheimer's & Dementia suggests that there could actually be a single, simple cause of Alzheimer's disease.
This hypothesis is pretty radical, and goes against what most experts in the field believe. But understanding the root cause (or causes) can help prevent, diagnose, and treat Alzheimer's in the future.
Here's what one new scientific model suggests about Alzheimer's cause, and what it means for us.
Meet the experts: Carol Huseby, PhD, is assistant professor in the Banner Neurodegenerative Disease Research Center at Arizona State University; Verna Porter, MD, is a neurologist and director of the Dementia, Alzheimer's Disease, and Neurocognitive Disorders at Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, CA. Michal Schnaider Beeri, PhD, is the director of the Herbert and Jacqueline Krieger Klein Alzheimer's Research Center at Rutgers Robert Wood Johnson Medical School
The study analyzed existing research and data, including a 2022 study that found most biological pathways can be linked to Alzheimer's disease, and proposed that "stress granules" may be the reason Alzheimer's disease develops in some people and not others.
Specifically, the researchers explored how the presence of these "stress granules" disrupt molecule movement between a cell's nucleus (the center part of a cell that contains genetic material) and its cytoplasm (the jelly-like substance that surrounds the nucleus where important chemical processes occur). The disruptions mess with a slew of essential biological processes, including cell survival and metabolism, and gene expression, the researchers theorized. The changes in gene expression then lead to some of the key markers seen in Alzheimer's patients: tau protein tangles and inflammation.
It's important to point out that this hypothesis is based on a scientific model using available data—not something that has been tested and proven.
What are "stress granules" and how are they connected to Alzheimer's?
As the paper explains, "stress granules" are basically clumps of proteins and RNA (a nucleic acid in cells with similar structures to DNA) that form when a cell is under stress.
These clumps form temporarily in the cell in response to stress in the environment. They help the cell press "pause" on normal functioning until it recovers.
Under normal circumstances, these "stress granules" actually serve an important purpose: helping protect the cell, then dissolving when the stressful event is over. But in people with Alzheimer's disease, the granules seem don't dissolve, which keeps essential molecules from moving in and out of the cell's nucleus as they normally would, explains study co-author Carol Huseby, PhD, assistant professor in the Banner Neurodegenerative Disease Research Center at Arizona State University.
'If stress is chronic, the cell's normal business is affected, such as making new molecules, transporting molecules, and recycling of molecules,' she says. That can eventually harm the cell and could lead to the progression of Alzheimer's disease.
It's important to note that the scientists are talking about biological stress here, not psychological. "The 'stress' causing these granules in biology is different from emotional stress," says Michal Schnaider Beeri, PhD, director of the Herbert and Jacqueline Krieger Klein Alzheimer's Research Center at Rutgers Robert Wood Johnson Medical School. "Biological stress refers to various challenges to the cell. Emotional stress, while it can have physical effects, is a psychological experience. While both types of stress can impact health, they operate through very different mechanisms at the cellular level."
There are a lot of potential stressors that cause these granules to form, including exposure to toxins, traumatic brain injury, viruses, oxidative stress, and genetic mutations, Huseby says. Getting sick or being exposed to things like pollution and pesticides can also put stress on your body—and your cells.
While this study suggests there could be a link between cell stress and Alzheimer's, there is also an established link between psychological stress and the disease.
'Chronic stress increases cortisol levels, which can shrink the hippocampus,' says Verna Porter, MD, is a neurologist and director of the Dementia, Alzheimer's Disease, and Neurocognitive Disorders at Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, CA. (The hippocampus is involved in learning and memory.) Having anxiety and depression is also linked with a higher risk of dementia, she points out.
Overall, 'all indications point to cell stress as occurring early in disease,' Huseby says. 'The key to understanding Alzheimer's disease is to understand when the disease is first detected before too many neurons are lost,' she continues. 'This information will lead to the most effective early treatments for Alzheimer's disease.'
Again, there's a lot experts still don't know about why some people end up developing Alzheimer's disease. And this study is just one hypothesis. But taking these steps may help lower your risk, according to the Alzheimer's Association:
Exercise regularly
Quit smoking (or don't pick up the habit!)
Manage high blood pressure and diabetes
Eat a heart-healthy diet
Try to maintain a healthy weight
Stay socially connected
Stimulate your brain with new activities and challenges
Doing what you can to manage stress levels, like practicing mindfulness, meditating, or doing relaxing hobbies, may also help, Dr. Porter says.
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Experts Say This Type Of Exercise Is The 'Fountain Of Youth'— Especially If You're Over 50
Aging gracefully isn't just about staying active; it's about choosing the right kind of activity to support your health. Resistance training (such as bodyweight, free weight, and resistance band exercises) is one of the best ways to counter the effects of aging, helping you build up muscle to support daily activities and prevent conditions like osteopenia and osteoporosis that can lead to bone fractures. And even if you've never lifted a weight before, it's never too late to start. 'Weight training is the fountain of youth,' says Abby Bales, PT, DPT, CSCS, founder of Reform Physical Therapy. 'Not only does it help increase and maintain bone density to prevent fractures, but the muscle mass that weight training builds also helps to regulate our blood sugar and metabolism.' Weight lifting can even improve balance and coordination, decreasing the frequency, severity, and likelihood of falls. On top of the physical benefits, resistance training has shown promise in staving off neurological conditions like Alzheimer's and dementia, according to a 2023 study published in Frontiers in Neuroscience, making it a multi-benefit tool for aging well. You can think of lifting weights as your body's best tool to promote resilience, energy, and independence through the aging process. Starting with small, manageable steps—such as incorporating resistance bands or light weights (at first) into your routine—can help you gain confidence and momentum while reaping the long-term benefits. Remember: Building a strength training routine doesn't have to be complicated—it just needs to be consistent. 'Start small, build gradually, and stick with it,' says Bales. She recommends starting with two or three sessions per week. Try rotating between upper body, lower body, and core exercises to keep things balanced. Progress takes time, so be patient. 'Results usually show in six to eight weeks,' Bales explains. The key is to keep showing up and enjoy the process—your future self will thank you. Need some inspiration to get started? Weight lifting later in life doesn't come without its fair share of challenges, but the rewards far outweigh the hurdles. Take it from these inspiring women, who spoke with WH previously about their later-in-life strength training journeys: Marilynn Larkin says not to let fear or self-consciousness hold you back. 'Feel your fear, then go through it,' she previously told WH. Following a cancer diagnosis, lifting weights became a way to push through her fears and embrace all that her body was capable of. '[Weight lifting] is all about allowing your body to reach its full potential and accepting it as it is.' Ginny MacColl recommends starting with a small yet challenging goal and celebrating each milestone—no matter how small, focusing on progress, not perfection. 'Little by little, these small steps lead to big changes,' she previously told WH, after becoming the oldest woman to complete an obstacle on American Ninja Warrior and breaking a Guinness World Record as a result. 'Instead of letting negativity and thoughts like 'I can't' creep in, I focus on getting stronger, physically and mentally. It works.' Michelle Alber says don't wait. After just 18 months of training focused on progressive overload (gradually increasing the weight and intensity of her workouts) and working with a coach to ensure her routine was safe and effective, she reversed her osteoporosis. 'There is never a 'perfect' time to start or a 'right' time to do anything,' she previously told WH. 'Was it hard to make major lifestyle changes at 65? Yes! But it's about choosing your 'hard' and taking control of your life.' You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals


Business Upturn
2 hours ago
- Business Upturn
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.